Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 2Myelodysplastic Syndromes 2beta-Thalassemia 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 21fludarabine 18Biopsy 18Cyclophosphamide 17fludarabine phosphate 14Cytarabine 13Whole-Body Irradiation 11venetoclax 10Tacrolimus 10Mycophenolic Acid 10Busulfan 10X-Rays 9Melphalan 9decitabine and cedazuridine drug combination 8asciminib 8Magnetic Resonance Spectroscopy 8Injections 8Granulocyte Colony-Stimulating Factor 7Cyclosporine 7Azacitidine 7ruxolitinib 6Sirolimus 6Nuclear Medicine Department, Hospital 6Thiotepa 5Stem Cell Transplantation 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Idarubicin 5Filgrastim 5CPX-351 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
luspatercept × Myeloid × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡